Do analysts recommend SSTI or GRDX?

SoundThinking currently has a consensus price target of $9.79, suggesting a potential upside of 17.62%. Given SoundThinking's stronger consensus rating and higher possible upside, equities research analysts clearly believe SoundThinking is more favorable than Entero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SoundThinking 1 Sell rating(s) 8 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.89 Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate RDZN or GRDX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Roadzen 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend GRDX or SNCR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Synchronoss Technologies 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Do analysts recommend MWC or GRDX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Micware 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings and valuation, MWC or GRDX?

Micware has higher revenue and earnings than Entero Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Micware $140.31M 0.66 $10.27M N/A N/A Entero Therapeutics $40K 682.70 -$6.39M -$1.90 N/A

Is MWC or GRDX more profitable?

Micware's return on equity of 0.00% beat Entero Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Micware N/A N/A N/A Entero Therapeutics N/A -47.34% -16.07%

Do analysts rate GRDX or BVC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Bitventures 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, GRDX or BVC?

Bitventures has higher revenue and earnings than Entero Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Entero Therapeutics $40K 682.70 -$6.39M -$1.90 N/A Bitventures $28.02M 3.39 -$5.37M N/A N/A

Is GRDX or BVC more profitable?

Bitventures' return on equity of 0.00% beat Entero Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Entero Therapeutics N/A -47.34% -16.07% Bitventures N/A N/A N/A

Entero Therapeutics (GRDX) Competitors

$3.83 +0.02 (+0.52%)

Closing price 04:00 PM Eastern

Extended Trading

$3.80 -0.03 (-0.78%)

As of 07:30 PM Eastern

Compare

GRDX vs. SSTI, RDZN, SNCR, MWC, and BVC

Should you buy Entero Therapeutics stock or one of its competitors? Entero Therapeutics's main competitors and comparable companies include SoundThinking (SSTI), Roadzen (RDZN), Synchronoss Technologies (SNCR), Micware (MWC), and Bitventures (BVC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "application software" industry.

How does Entero Therapeutics compare to SoundThinking?

SoundThinking (NASDAQ:SSTI) and Entero Therapeutics (NASDAQ:GRDX) are both small-cap technology companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

Entero Therapeutics has lower revenue, but higher earnings than SoundThinking. SoundThinking is trading at a lower price-to-earnings ratio than Entero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SoundThinking	$97.96M	1.10	-$9.42M	-$1.29	N/A
Entero Therapeutics	$40K	682.70	-$6.39M	-$1.90	N/A

SoundThinking has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.69, meaning that its stock price is 69% more volatile than the broader market.

60.7% of SoundThinking shares are held by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are held by institutional investors. 10.9% of SoundThinking shares are held by insiders. Comparatively, 0.8% of Entero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Entero Therapeutics has a net margin of 0.00% compared to SoundThinking's net margin of -16.92%. SoundThinking's return on equity of -23.77% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SoundThinking	-16.92%	-23.77%	-12.90%
Entero Therapeutics	N/A	-47.34%	-16.07%

In the previous week, SoundThinking had 20 more articles in the media than Entero Therapeutics. MarketBeat recorded 20 mentions for SoundThinking and 0 mentions for Entero Therapeutics. SoundThinking's average media sentiment score of 0.42 beat Entero Therapeutics' score of 0.00 indicating that SoundThinking is being referred to more favorably in the media.

Company	Overall Sentiment
SoundThinking	Neutral
Entero Therapeutics	Neutral

SoundThinking currently has a consensus price target of $9.79, suggesting a potential upside of 17.62%. Given SoundThinking's stronger consensus rating and higher possible upside, equities research analysts clearly believe SoundThinking is more favorable than Entero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SoundThinking	1 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.89
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

SoundThinking beats Entero Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Entero Therapeutics compare to Roadzen?

Roadzen (NASDAQ:RDZN) and Entero Therapeutics (NASDAQ:GRDX) are both small-cap technology companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

Entero Therapeutics has lower revenue, but higher earnings than Roadzen. Roadzen is trading at a lower price-to-earnings ratio than Entero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roadzen	$55.02M	1.84	-$22.52M	-$0.36	N/A
Entero Therapeutics	$40K	682.70	-$6.39M	-$1.90	N/A

Roadzen has a beta of 1.25, meaning that its stock price is 25% more volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.69, meaning that its stock price is 69% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roadzen	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Entero Therapeutics has a net margin of 0.00% compared to Roadzen's net margin of -46.90%. Roadzen's return on equity of 0.00% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roadzen	-46.90%	N/A	-45.21%
Entero Therapeutics	N/A	-47.34%	-16.07%

In the previous week, Roadzen had 2 more articles in the media than Entero Therapeutics. MarketBeat recorded 2 mentions for Roadzen and 0 mentions for Entero Therapeutics. Roadzen's average media sentiment score of 0.00 equaled Entero Therapeutics'average media sentiment score.

Company	Overall Sentiment
Roadzen	Neutral
Entero Therapeutics	Neutral

24.7% of Roadzen shares are owned by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are owned by institutional investors. 29.5% of Roadzen shares are owned by company insiders. Comparatively, 0.8% of Entero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Roadzen beats Entero Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Entero Therapeutics compare to Synchronoss Technologies?

Entero Therapeutics (NASDAQ:GRDX) and Synchronoss Technologies (NASDAQ:SNCR) are both small-cap technology companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

12.3% of Entero Therapeutics shares are owned by institutional investors. Comparatively, 51.7% of Synchronoss Technologies shares are owned by institutional investors. 0.8% of Entero Therapeutics shares are owned by company insiders. Comparatively, 19.9% of Synchronoss Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Synchronoss Technologies has higher revenue and earnings than Entero Therapeutics. Synchronoss Technologies is trading at a lower price-to-earnings ratio than Entero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	$40K	682.70	-$6.39M	-$1.90	N/A
Synchronoss Technologies	$170.91M	0.61	$6.17M	-$1.02	N/A

Entero Therapeutics has a net margin of 0.00% compared to Synchronoss Technologies' net margin of -5.69%. Synchronoss Technologies' return on equity of 24.44% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-47.34%	-16.07%
Synchronoss Technologies	-5.69%	24.44%	3.59%

In the previous week, Entero Therapeutics' average media sentiment score of 0.00 equaled Synchronoss Technologies'average media sentiment score.

Company	Overall Sentiment
Entero Therapeutics	Neutral
Synchronoss Technologies	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Synchronoss Technologies	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Entero Therapeutics has a beta of 1.69, suggesting that its stock price is 69% more volatile than the broader market. Comparatively, Synchronoss Technologies has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market.

Summary

Synchronoss Technologies beats Entero Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Entero Therapeutics compare to Micware?

Micware (NASDAQ:MWC) and Entero Therapeutics (NASDAQ:GRDX) are both small-cap technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

In the previous week, Micware's average media sentiment score of 0.00 equaled Entero Therapeutics'average media sentiment score.

Company	Overall Sentiment
Micware	Neutral
Entero Therapeutics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Micware	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

12.3% of Entero Therapeutics shares are held by institutional investors. 0.8% of Entero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Micware has higher revenue and earnings than Entero Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Micware	$140.31M	0.66	$10.27M	N/A	N/A
Entero Therapeutics	$40K	682.70	-$6.39M	-$1.90	N/A

Micware's return on equity of 0.00% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Micware	N/A	N/A	N/A
Entero Therapeutics	N/A	-47.34%	-16.07%

Summary

Micware beats Entero Therapeutics on 5 of the 8 factors compared between the two stocks.

How does Entero Therapeutics compare to Bitventures?

Entero Therapeutics (NASDAQ:GRDX) and Bitventures (NASDAQ:BVC) are both small-cap technology companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, dividends, risk, institutional ownership and earnings.

Bitventures has higher revenue and earnings than Entero Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	$40K	682.70	-$6.39M	-$1.90	N/A
Bitventures	$28.02M	3.39	-$5.37M	N/A	N/A

12.3% of Entero Therapeutics shares are held by institutional investors. 0.8% of Entero Therapeutics shares are held by insiders. Comparatively, 84.6% of Bitventures shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Bitventures' return on equity of 0.00% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-47.34%	-16.07%
Bitventures	N/A	N/A	N/A

In the previous week, Entero Therapeutics' average media sentiment score of 0.00 equaled Bitventures'average media sentiment score.

Company	Overall Sentiment
Entero Therapeutics	Neutral
Bitventures	Neutral

Entero Therapeutics has a beta of 1.69, meaning that its stock price is 69% more volatile than the broader market. Comparatively, Bitventures has a beta of -1.14, meaning that its stock price is 214% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Bitventures	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Bitventures beats Entero Therapeutics on 6 of the 9 factors compared between the two stocks.

Get Entero Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GRDX vs. The Competition

Export

Metric	Entero Therapeutics	Software Industry	Technology Sector	NASDAQ Exchange
Market Cap	$27.17M	$16.24B	$31.93B	$13.26B
Dividend Yield	N/A	3.42%	2.75%	17.34%
P/E Ratio	-2.02	145.13	82.05	26.20
Price / Sales	682.70	1,281.52	585.81	88.34
Price / Cash	N/A	43.04	48.60	34.70
Price / Book	0.52	8.88	8.22	6.40
Net Income	-$6.39M	$429.52M	$766.00M	$381.07M
7 Day Performance	10.37%	1.98%	1.82%	-0.65%
1 Month Performance	17.85%	-1.16%	0.36%	-4.51%
1 Year Performance	N/A	1.79%	168.87%	1.82%

Entero Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GRDX Entero Therapeutics	0.7986 of 5 stars	$3.83 +0.5%	N/A	N/A	$27.17M	$40K	N/A	2	High Trading Volume
SSTI SoundThinking	2.4368 of 5 stars	$8.33 -1.3%	$9.79 +17.5%	-30.5%	$107.91M	$104.13M	N/A	305	Analyst Forecast
RDZN Roadzen	0.2787 of 5 stars	$1.22 -0.4%	N/A	+18.4%	$103.90M	$55.02M	N/A	459	Gap Up
SNCR Synchronoss Technologies	N/A	$9.00 flat	N/A	N/A	$103.56M	$170.91M	N/A	1,540
MWC Micware	N/A	$1.69 -1.7%	N/A	N/A	$100.42M	$140.31M	N/A	483

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GRDX) was last updated on 10/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Entero Therapeutics (GRDX) Competitors

GRDX vs. SSTI, RDZN, SNCR, MWC, and BVC

How does Entero Therapeutics compare to SoundThinking?

Summary

How does Entero Therapeutics compare to Roadzen?

Summary

How does Entero Therapeutics compare to Synchronoss Technologies?

Summary

How does Entero Therapeutics compare to Micware?

Summary

How does Entero Therapeutics compare to Bitventures?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRDX vs. The Competition

Entero Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Entero Therapeutics (GRDX) Competitors

GRDX vs. SSTI, RDZN, SNCR, MWC, and BVC

How does Entero Therapeutics compare to SoundThinking?

Which has better earnings & valuation, SSTI or GRDX?

Which has more risk and volatility, SSTI or GRDX?

Do insiders and institutionals have more ownership in SSTI or GRDX?

Is SSTI or GRDX more profitable?

Does the media prefer SSTI or GRDX?

Do analysts recommend SSTI or GRDX?

Summary

How does Entero Therapeutics compare to Roadzen?

Which has preferable valuation and earnings, RDZN or GRDX?

Which has more volatility & risk, RDZN or GRDX?

Do analysts rate RDZN or GRDX?

Is RDZN or GRDX more profitable?

Does the media favor RDZN or GRDX?

Do insiders & institutionals hold more shares of RDZN or GRDX?

Summary

How does Entero Therapeutics compare to Synchronoss Technologies?

Do institutionals and insiders hold more shares of GRDX or SNCR?

Which has better valuation and earnings, GRDX or SNCR?

Is GRDX or SNCR more profitable?

Does the media refer more to GRDX or SNCR?

Do analysts recommend GRDX or SNCR?

Which has more risk & volatility, GRDX or SNCR?

Summary

How does Entero Therapeutics compare to Micware?

Does the media favor MWC or GRDX?

Do analysts recommend MWC or GRDX?

Do institutionals and insiders have more ownership in MWC or GRDX?

Which has preferable earnings and valuation, MWC or GRDX?

Is MWC or GRDX more profitable?

Summary

How does Entero Therapeutics compare to Bitventures?

Which has better earnings & valuation, GRDX or BVC?

Do institutionals & insiders believe in GRDX or BVC?

Is GRDX or BVC more profitable?

Does the media refer more to GRDX or BVC?

Which has more volatility & risk, GRDX or BVC?

Do analysts rate GRDX or BVC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRDX vs. The Competition

Entero Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools